PT2606125T - Células que expressam características th1 e propriedades citolíticas - Google Patents

Células que expressam características th1 e propriedades citolíticas

Info

Publication number
PT2606125T
PT2606125T PT118188846T PT11818884T PT2606125T PT 2606125 T PT2606125 T PT 2606125T PT 118188846 T PT118188846 T PT 118188846T PT 11818884 T PT11818884 T PT 11818884T PT 2606125 T PT2606125 T PT 2606125T
Authority
PT
Portugal
Prior art keywords
citrolytic
express
cells
properties
citrolytic properties
Prior art date
Application number
PT118188846T
Other languages
English (en)
Portuguese (pt)
Inventor
Har-Noy Michael
Original Assignee
Immunovative Therapies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovative Therapies Ltd filed Critical Immunovative Therapies Ltd
Publication of PT2606125T publication Critical patent/PT2606125T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • C12N5/0638Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5158Antigen-pulsed cells, e.g. T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/51B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/515CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
PT118188846T 2010-08-20 2011-08-22 Células que expressam características th1 e propriedades citolíticas PT2606125T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40188110P 2010-08-20 2010-08-20
US201161495055P 2011-06-09 2011-06-09

Publications (1)

Publication Number Publication Date
PT2606125T true PT2606125T (pt) 2018-02-27

Family

ID=45594250

Family Applications (1)

Application Number Title Priority Date Filing Date
PT118188846T PT2606125T (pt) 2010-08-20 2011-08-22 Células que expressam características th1 e propriedades citolíticas

Country Status (19)

Country Link
US (3) US20120045423A1 (https=)
EP (1) EP2606125B1 (https=)
JP (2) JP6408219B2 (https=)
KR (1) KR101900807B1 (https=)
CN (2) CN103068973A (https=)
AU (1) AU2011291477B2 (https=)
BR (1) BR112013003989B1 (https=)
CA (1) CA2808873C (https=)
DK (1) DK2606125T3 (https=)
ES (1) ES2660577T3 (https=)
HU (1) HUE036094T2 (https=)
IL (1) IL224813B (https=)
NO (1) NO2606125T3 (https=)
PH (1) PH12013500519B1 (https=)
PL (1) PL2606125T3 (https=)
PT (1) PT2606125T (https=)
SG (2) SG10201510524TA (https=)
TR (1) TR201802334T4 (https=)
WO (1) WO2012024666A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2660577T3 (es) * 2010-08-20 2018-03-23 Immunovative Therapies, Ltd. Células que expresan características y propiedades citolíticas de Th1
KR101697473B1 (ko) * 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
CN108064176A (zh) 2015-04-22 2018-05-22 库瑞瓦格股份公司 用于治疗肿瘤疾病的含有rna的组合物
EP3633029A4 (en) 2017-05-26 2021-06-09 Green Cross Lab Cell Corporation METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL
AU2019381526B2 (en) 2018-11-14 2023-02-23 Green Cross Lab Cell Corporation Method for culturing cord blood-derived natural killer cells using transformed T-cells
JP7337373B2 (ja) * 2019-07-29 2023-09-04 サイアス株式会社 抗原特異的t細胞の製造方法
US11730313B2 (en) * 2021-02-24 2023-08-22 Kirsten Wilkins Slow cooker liner system with integrated dividers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030050392A1 (en) * 1998-09-22 2003-03-13 Brother Kogyo Kabushiki Kaisha Water-based ink for ink jetting and ink jet recording method
US20030194395A1 (en) * 2001-09-17 2003-10-16 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
AU2002341717A1 (en) 2001-09-17 2003-04-01 Medcell Biologics, Llc. Cell therapy system
US20030134415A1 (en) 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
ES2340270T3 (es) 2002-08-23 2010-06-01 Gabriele Prof. Dr. Multhoff Granzima b dependiente de peptidos hsp70/hsp70 como inductora de apoptosis en celulas tumorales.
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US7435592B2 (en) * 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
CA2555714C (en) * 2004-02-26 2013-12-03 Immunovative Therapies, Ltd. Methods for preparing t-cells for cell therapy
ES2660577T3 (es) 2010-08-20 2018-03-23 Immunovative Therapies, Ltd. Células que expresan características y propiedades citolíticas de Th1

Also Published As

Publication number Publication date
NO2606125T3 (https=) 2018-04-21
JP2013536232A (ja) 2013-09-19
CN103068973A (zh) 2013-04-24
KR20130103485A (ko) 2013-09-23
US20130195825A1 (en) 2013-08-01
BR112013003989B1 (pt) 2020-11-24
JP2017061558A (ja) 2017-03-30
SG10201510524TA (en) 2016-01-28
EP2606125A4 (en) 2014-03-19
AU2011291477B2 (en) 2016-07-28
PH12013500519A1 (en) 2013-05-06
JP6408219B2 (ja) 2018-10-17
US20130196428A1 (en) 2013-08-01
EP2606125B1 (en) 2017-11-22
PH12013500519B1 (en) 2020-06-26
AU2011291477A1 (en) 2013-04-04
SG187846A1 (en) 2013-03-28
CA2808873A1 (en) 2012-02-23
DK2606125T3 (en) 2018-03-05
PL2606125T3 (pl) 2018-05-30
CA2808873C (en) 2020-02-18
ES2660577T3 (es) 2018-03-23
US20120045423A1 (en) 2012-02-23
KR101900807B1 (ko) 2018-11-08
BR112013003989A2 (pt) 2017-11-14
IL224813B (en) 2020-06-30
CN108245673A (zh) 2018-07-06
US10385315B2 (en) 2019-08-20
WO2012024666A3 (en) 2012-05-18
EP2606125A2 (en) 2013-06-26
WO2012024666A2 (en) 2012-02-23
JP6525946B2 (ja) 2019-06-05
TR201802334T4 (tr) 2018-03-21
HUE036094T2 (hu) 2018-06-28

Similar Documents

Publication Publication Date Title
IL269045A (en) Aptamers and uses thereof
IL272325B (en) Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
BR112013009069A2 (pt) instrumentação unida ao paciente e métodos
PL3199024T3 (pl) Zastosowanie kompozycji cyklodekstryny i stosowne sposoby
EP2870505A4 (en) TRANSPARENT GLOSS AND GLOSS PROTECTION STRUCTURES
CO7071096A2 (es) Anticuerpos anti-lgr5 e inmunoconjugados
BR112015002193A2 (pt) anticorpos anti-etbr e imunoconjugados
BR112012031855A2 (pt) composição e artigo
IL223295A (en) Lung cancer biomarkers and uses thereof
BR112012017441A2 (pt) compostos e métodos
EP2834725A4 (en) TEXT SELECTION AND INPUT
BR112013023776A2 (pt) composição e abertura vedada com selante
DK2433574T3 (da) Patellaresektionsføring og -arrangement
BR112012027165A2 (pt) composição e artigo
IL238227A0 (en) Anti-c16orf54 antibodies and methods of use thereof
HRP20160922T1 (hr) Oligopeptidni spojevi i njihove uporabe
EP2701730A4 (en) MFG-E8 AND USES THEREOF
EP2558137A4 (en) PROCESS AND COMBINATION
PL2612904T3 (pl) Kompozycje przeciwpróchnicze i probiotyki/prebiotyki
BR112013010074A2 (pt) composição celulósica e produto
BR112012028633A2 (pt) composição reticulada e artigo
CL2015000111A1 (es) Colectores que contienen monotiofosfato y metodos
PT2606125T (pt) Células que expressam características th1 e propriedades citolíticas
BR112013015275A2 (pt) c-semi com forças hidrodinâmicas mínimas
FI20105938L (fi) Valojohde ja sen valmistus